Key features and details | |
Cat. No. | MABL-3203 |
Name | Anti-VEGFR2 mAbs |
Clone No. | AFD- IMC-1121B (Ramucirumab) |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | crystallography, in vitro, in vivo, therapeutic, FC, IHC |
Species Reactivity | Human |
Basic Information | |
Specificity | The antibody specifically recognizes VEGFR-2 and it binds to domain 3 of VEGFR2. VEGFR2 is a tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. It plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. |
Alternative Name | Vascular endothelial growth factor receptor 2; kinase ｉｎｓｅｒｔ domain- containing receptor; KDR; Fetal liver kinase 1; FLK-1; Kinase ｉｎｓｅｒｔ domain receptor; Protein-tyrosine kinase receptor flk-1; CD309; VEGFR-2; Cyramza; LY3009806; 947687-13-0 |
UniProt | P35968 |
Immunogen | The original antibody was generated by using phage display technology. A new library comprising the single VH paired with the variable light chain (VL) repertoire obtained from the original naıve human library was constructed, followed by phage display-based selection. |
Application Notes | The antibody blocked the VEGFR2/VEG interaction with an IC50 value of 1 nM and 0.8 nM for Fab and IgG1 fragments respectively. The binding affinity of the Fab and IgG fragments to VEGFR-2 was measured by surface plasmon resonance (Kd= 100 pM and 50 pM respectively). The IgG1 fragment was able to inhibit VEGF-stimulated VEGFR2 phosphorylation in endothelial cells. The epitope mapping of this antibody demonstrated the antibody interacted with the third immunoglobulin domain within the extracellular region of VEGFR2 (Lu et al, 2003; pmid:12917408). The antibody (IgG1) strongly inhibited VEGF-induced migration of human leukemia cells in vitro, and when administered in vivo, significantly prolonged survival of NOD-SCID mice inoculated with human leukemia cells. (Zhu et al, 2003; pmid:12646950). |
Antibody First Published | Lu et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem. 2003 Oct 31;278(44):43496-507. PMID:12917408 |
Note on publication | The article describes the generation and characterization of the antibody. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
